Cihoric, Nikola; Savic, Mirjana; Schneider, Sabine; Ackermann, I; Bichsel-Naef, Mirjam; Schmid, Ralph; Lardinois, D; Gugger, M; Bubendorf, Lukas; Zlobec, Inti; Tapia, Coya (2014). Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer. British journal of cancer, 110(12), pp. 2914-2922. Nature Publishing Group 10.1038/bjc.2014.229
|
Text
bjc2014229a.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-Share Alike (CC-BY-NC-SA). Download (579kB) | Preview |
Background:Recently, fibroblast growth factor receptor 1 (FGFR1) was discovered in squamous cell carcinomas (SCC) of the lung with FGFR1 amplification described as a promising predictive marker for anti-FGFR inhibitor treatment. Only few data are available regarding prevalence, prognostic significance and clinico-pathological characteristics of FGFR1-amplified and early-stage non-small cell lung carcinomas (NSCLC). We therefore investigated the FGFR1 gene status in a large number of well-characterised early-stage NSCLC.Methods:FGFR1 gene status was evaluated using a commercially available fluorescent in situ hybridisation (FISH) probe on a tissue microarray (TMA). This TMA harbours 329 resected, formalin-fixed and paraffin-embedded, nodal-negative NSCLC with a UICC stage I-II. The FISH results were correlated with clinico-pathological features and overall survival (OS).Results:The prevalence of an FGFR1 amplification was 12.5% (41/329) and was significantly (P<0.0001) higher in squamous cell carcinoma (SCC) (20.7%) than in adenocarcinoma (2.2%) and large cell carcinoma (13%). Multivariate analysis revealed significantly (P=0.0367) worse 5-year OS in patients with an FGFR1-amplified NSCLC.Conclusions:FGFR1 amplification is common in early-stage SCC of the lung and is an independent and adverse prognostic marker. Its potential role as a predictive marker for targeted therapies or adjuvant treatment needs further investigation.
Actions (login required)
 |
Edit item |